Primary treatment of zygomycosis with liposomal amphotericin B: Analysis of 28 cases

Medical Mycology

Volumn 48, Issue 3, 2010, Pages 511-517

  Shoham, Shmuel ^a   Magill, Shelley S ^b,c   Merz, William G ^c   Gonzalez, Corina ^d   Seibel, Nita ^e   Buchanan, Wendy L ^f   Knudsen, Tena A ^f   Sarkisova, Tatyana A ^f   Walsh, Thomas J ^f  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Hematopoietic stem cell transplantation; Leukemia; Liposomal amphotericin B; Rhizopus oryzae; Zygomycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE STUDY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRANULOCYTE TRANSFUSION; HUMAN; IMMUNE DEFICIENCY; INFANT; LEUKEMIA; LUNG DISEASE; LYMPHOMA; MALE; MUCORMYCOSIS; MYELODYSPLASTIC SYNDROME; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PRESCHOOL CHILD; RHIZOPUS; SCHOOL CHILD; SKIN DISEASE; SOLID TUMOR; SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DEBRIDEMENT; FEMALE; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT; ZYGOMYCOSIS;

RHIZOPUS; RHIZOPUS ORYZAE;

EID: 77950562567     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903311944     Document Type: Article

References (37)

1. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
2. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002; 16: 895-914, vi.
3. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17: 517-525.
4. Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006; 44: 335-342. (Pubitemid 43922068)
5. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 25: 215-229. (Pubitemid 43800540)
6. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: 588-590.
7. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851-856.
8. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360. (Pubitemid 40503665)
9. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-952. (Pubitemid 38252550)
10. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584-587. (Pubitemid 39120940)
11. Spellberg B, Edwards J, Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-569. (Pubitemid 40995116)
12. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917. (Pubitemid 34229758)
13. Sims CR, Ostrosky-Zeichner L. Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. Arch Med Res 2007; 38: 90-93. (Pubitemid 44894615)
14. Tang D, Wang W. Successful cure of an extensive burn injury complicated with Mucor wound sepsis. Burns 1998; 24: 72-73. (Pubitemid 28195789)
15. Hopkins RJ, Rothman M, Fiore A, Goldblum SE. Cerebral mucormycosis associated with intravenous drug use: three case reports and review. Clin Infect Dis 1994; 19: 1133-1137. (Pubitemid 24380030)
16. Nagy-Agren SE, Chu P, Smith GJ, Waskin HA, Altice FL. Zygomycosis (mucormycosis) and HIV infection: report of three cases and review. J Acquir Immune Defi c Syndr Hum Retrovirol 1995; 10: 441-449.
17. Almyroudis NG, Sutton DA, Linden P, et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6: 2365-2374. (Pubitemid 44359422)
18. Larkin J, Montero J. Effi cacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003; 20: 201-206. (Pubitemid 36511530)
19. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40(Suppl. 6): S401-408.
20. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001; 20: 460-466. (Pubitemid 34212106)
21. Linden P, Williams P, Chan KM. Effi cacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 2000; 14(4 Pt 1): 329-339.
22. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and effi cacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396.
23. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised defi nitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
24. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693. (Pubitemid 32221925)
25. Patterson RM, Ackerman GL. Renal tubular acidosis due to amphotericin B nephrotoxicity. Arch Intern Med 1971; 127: 241-244.
26. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771. (Pubitemid 29114295)
27. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other fi lamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487-3496. (Pubitemid 33107867)
28. Cornely OA, Maertens J, Bresnik M, and AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297.
29. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-1751.
30. Spellberg B, Edwards J, Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-569. (Pubitemid 40995116)
31. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-371. (Pubitemid 352009357)
32. Groll AH, Lyman CA, Petraitis V, et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006; 50: 3418-3423. (Pubitemid 44527518)
33. Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al. Interferongamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005; 191: 1180-1187. (Pubitemid 40404378)
34. Rodríguez MM, Calvo E, Mariné M, et al. Effi cacy of liposomal amphotericin B combined with interferon-gamma or granulocyte- macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice. Antimicrob Agents Chemothe 2009: 53: 3569-3571.
35. Walsh TJ, Kontoyiannis DP. What is the role of combination therapy in management of zygomycosis? Invited Editorial. Clin Infect Dis 2008; 47: 372-374.
36. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-273.
37. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004; 45: 1351-1360. (Pubitemid 38701909)